CR HOLDINGS(01911),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

01911 CR HOLDINGS

Pre-opening 03-26 09:09:42

3.430

+0.000

0.00%

High3.430	Low3.430	Vol0.00
Open3.430	D1 Closing3.430	Amplitude0.00%
Mkt Cap1.97B	Tradable Cap1.97B	Total Shares573.00M
T/O0.00	T/O Rate0.00%	Tradable Shares573.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"01911","market":"HK","secType":"STK","nameCN":"CR HOLDINGS","latestPrice":3.43,"timestamp":1774486811265,"preClose":3.43,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":573000000,"shares":573000000,"eps":-0.349837,"marketStatus":"Pre-opening","change":0,"latestTime":"03-26 09:09:42","open":3.43,"high":3.43,"low":3.43,"amount":0,"amplitude":0,"askPrice":3.5,"askSize":10000,"bidPrice":3.32,"bidSize":80000,"shortable":3,"etf":0,"ttmEps":-0.077,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774488600000},"marketStatusCode":1,"adr":0,"listingDate":1537977600000,"exchange":"SEHK","adjPreClose":3.43,"openAndCloseTimeList":[[1774488600000,1774497600000],[1774501200000,1774512000000]],"volumeRatio":0,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01911","defaultTab":"news","newsList":[{"id":"2622011819","title":"Innovent clarifies Lilly collaboration is not an acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2622011819","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622011819?lang=en_us&edition=fundamental","pubTime":"2026-03-25 07:00","pubTimestamp":1774393254,"startTime":"0","endTime":"0","summary":"Innovent said its strategic collaboration agreement with Lilly became effective after the company received early clearance from the US Federal Trade Commission.The company said some media reports incorrectly interpreted the agreement’s effectiveness as an acquisition of Innovent.Innovent said it is not engaged in, and has no intention of pursuing, an acquisition transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 24, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL5BMNlK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242644610.SGD","LU2097828805.USD","LU2097828474.EUR","LU2097828631.EUR","BK1583","LU2097828557.USD","LU2328871848.SGD","01801","LU2488822045.USD","LU1969619763.USD","LU0502904849.HKD","LU2097828714.EUR","LU0455707207.USD","01911","BK1147","BK1589","HK0000165453.HKD","BK1161"],"gpt_icon":0},{"id":"2621033414","title":"Innovent Phase 3 STAR trial shows efdamrofusp alfa meets primary endpoint in nAMD with 72.8% at Q16W dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2621033414","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621033414?lang=en_us&edition=fundamental","pubTime":"2026-03-24 08:00","pubTimestamp":1774310422,"startTime":"0","endTime":"0","summary":"Innovent reported that the Phase 3 STAR registration study  of efdamrofusp alfa  in Chinese patients with neovascular age-related macular degeneration met its primary endpoint at Week 52.Mean best corrected visual acuity change from baseline at Week 52 was 10.37 ETDRS letters for IBI302 8 mg versus 10.11 letters for aflibercept 2 mg.During the maintenance period, 86.2% of participants in the IBI302 group reached dosing intervals of at least every 12 weeks, including 72.8% at every 16 weeks.Macular atrophy incidence at Week 52 was 1.5% with IBI302 and 2.9% with aflibercept.Innovent said follow-up is ongoing through 100 weeks and the complete dataset is expected to be presented at future academic conferences or published in peer-reviewed journals.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL880J53:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0502904849.HKD","01801","LU2097828557.USD","BK1161","LU2097828805.USD","LU2242644610.SGD","LU2097828714.EUR","LU2488822045.USD","HK0000165453.HKD","LU0455707207.USD","BK1583","LU2097828474.EUR","BK1589","LU2097828631.EUR","01911","LU1969619763.USD","LU2328871848.SGD","BK1147"],"gpt_icon":0},{"id":"2621742072","title":"Innovent doses first patient in 600-participant Phase 3 IBI128 gout trial versus febuxostat","url":"https://stock-news.laohu8.com/highlight/detail?id=2621742072","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621742072?lang=en_us&edition=fundamental","pubTime":"2026-03-23 08:00","pubTimestamp":1774224021,"startTime":"0","endTime":"0","summary":"Innovent reported that the first participant has been dosed in a randomized, double-blind, multi-center Phase 3 study of tigulixostat , a xanthine oxidase inhibitor, in Chinese patients with gout.The trial plans to enroll 600 patients and will randomize them 1:1 to tigulixostat 100 mg or febuxostat 40 mg for 24 weeks.The primary endpoint is the proportion of patients achieving serum uric acid below 360 μmol/L at week 24.Phase 2 data were previously presented at the 2025 Asia-Pacific League of Associations for Rheumatology conference, and the Phase 3 study is intended to assess longer-term outcomes over a one-year treatment period.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL10gZhx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01911","BK1161","LU2097828557.USD","LU2097828631.EUR","LU0502904849.HKD","LU2328871848.SGD","LU0455707207.USD","BK1583","LU1969619763.USD","LU2097828474.EUR","LU2097828714.EUR","BK1147","HK0000165453.HKD","LU2242644610.SGD","01801","BK1589","LU2097828805.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"1104295841","title":"CR HOLDINGS (01911) Issues Profit Alert, Anticipates Annual Profit Attributable to Shareholders of Approximately RMB 101.4 Million, Turning Loss into Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=1104295841","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104295841?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:11","pubTimestamp":1774005070,"startTime":"0","endTime":"0","summary":"CR HOLDINGS (01911) announced that the group expects to record a profit attributable to owners of the company of approximately RMB 101.4 million for the year ending December 31, 2025. This contrasts...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01911","BK1147"],"gpt_icon":0},{"id":"2620806527","title":"China Renaissance forecasts 2025 profit attributable to owners of RMB101.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620806527","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620806527?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:01","pubTimestamp":1774004467,"startTime":"0","endTime":"0","summary":"China Renaissance expects profit attributable to owners of about CNY101.4 million, versus a loss of about CNY179 million in the prior year.The outlook reflects a significant increase in operating profit from its investment management segment.Results also factor in a significant reduction in losses at China Renaissance Securities .The company cited lower operating expenses as another driver of the expected result.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Renaissance Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 20, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDLbxWkG5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01911","BK1147"],"gpt_icon":0},{"id":"2620780633","title":"China Renaissance - Expected Result Driven by Investment Management Segment Gains in FY, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2620780633","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620780633?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:00","pubTimestamp":1774004445,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nFWN4071G2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01911","BK1147"],"gpt_icon":0},{"id":"2620780529","title":"China Renaissance - Expects Profit Attributable of RMB101.4 Mln for Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2620780529","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620780529?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:00","pubTimestamp":1774004445,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nFWN4071G2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1147","01911"],"gpt_icon":0},{"id":"2618184384","title":"Innovent Biologics board to review annual results and consider final dividend recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2618184384","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618184384?lang=en_us&edition=fundamental","pubTime":"2026-03-12 16:35","pubTimestamp":1773304535,"startTime":"0","endTime":"0","summary":"Innovent Biologics will hold a board meeting on March 26, 2026 to consider and approve its annual results for the year ended December 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL2Tn5xB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0455707207.USD","LU2097828631.EUR","01911","BK1147","LU2242644610.SGD","01801","LU0502904849.HKD","HK0000165453.HKD","LU1969619763.USD","BK1583","LU2097828557.USD","LU2097828805.USD","LU2097828474.EUR","LU2328871848.SGD","BK1161","BK1589","LU2488822045.USD","LU2097828714.EUR"],"gpt_icon":0},{"id":"1103200658","title":"China Renaissance (01911) Announces Monthly Return on Movements in Securities for February 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1103200658","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103200658?lang=en_us&edition=fundamental","pubTime":"2026-03-03 15:21","pubTimestamp":1772522503,"startTime":"0","endTime":"0","summary":"China Renaissance Holdings Limited (01911) reported that as of 28 February 2026, its authorized share capital remained at 2.00 billion ordinary shares with a par value of USD 0.000025 each,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01911"],"gpt_icon":0},{"id":"2611190152","title":"Innovent Biologics Doses First Patient in Phase 3 Trial of Novel HER2 ADC for Advanced Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2611190152","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611190152?lang=en_us&edition=fundamental","pubTime":"2026-02-13 08:00","pubTimestamp":1770940820,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has announced the initiation of a pivotal Phase 3 clinical study, HeriCare-Breast01, evaluating IBI354—a HER2 monoclonal antibody-camptothecin derivative conjugate —as a first-line treatment for patients with unresectable locally advanced or metastatic HER2-positive breast cancer. The first participant has been successfully dosed in this study in China. IBI354 is also being investigated in another ongoing pivotal Phase 3 trial, HeriCare-Ovarian01. Early-stage studies have demonstrated a favorable safety and efficacy profile for IBI354, but the results of the current Phase 3 trial have not yet been presented and are anticipated in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL7Y3cHQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828714.EUR","BK1147","LU2328871848.SGD","01801","LU2242644610.SGD","LU0455707207.USD","LU2097828805.USD","LU0502904849.HKD","LU1969619763.USD","LU2097828474.EUR","BK1583","HK0000165453.HKD","01911","LU2097828557.USD","LU2488822045.USD","LU2097828631.EUR","BK1589","BK1161"],"gpt_icon":0},{"id":"2610991047","title":"Individual investors are China Renaissance Holdings Limited's (HKG:1911) biggest owners and were rewarded after market cap rose by HK$298m last week","url":"https://stock-news.laohu8.com/highlight/detail?id=2610991047","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610991047?lang=en_us&edition=fundamental","pubTime":"2026-02-12 08:36","pubTimestamp":1770856608,"startTime":"0","endTime":"0","summary":"Key Insights The considerable ownership by individual investors in China Renaissance Holdings indicates that they...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/7132000-choice2-main-header/1585186691278","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/7132000-choice2-main-header/1585186691278"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/diversified-financials/hkg-1911/china-renaissance-holdings-shares/news/individual-investors-are-china-renaissance-holdings-limiteds-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/diversified-financials/hkg-1911/china-renaissance-holdings-shares/news/individual-investors-are-china-renaissance-holdings-limiteds-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01911","BK1147"],"gpt_icon":0},{"id":"2609705575","title":"Innovent Announces Strategic Collaboration With Lilly To Develop New Medicines Globally In Oncology And Immunology","url":"https://stock-news.laohu8.com/highlight/detail?id=2609705575","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609705575?lang=en_us&edition=fundamental","pubTime":"2026-02-08 18:15","pubTimestamp":1770545735,"startTime":"0","endTime":"0","summary":"Feb 8 (Reuters) - Innovent Biologics Inc <1801.HK>::*INNOVENT ANNOUNCES STRATEGIC COLLABORATION WITH LILLY TO DEVELOP NEW MEDICINES GLOBALLY IN ONCOLOGY AND IMMUNOLOGY*INNOVENT BIOLOGICS - INNOVENT WI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260208:nRSD8YHxbZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828474.EUR","LU2097828805.USD","LU2242644610.SGD","HK0000165453.HKD","LU2097828631.EUR","LU0455707207.USD","LU2097828714.EUR","LU2488822045.USD","BK1589","LU2328871848.SGD","01801","LU0502904849.HKD","LU2097828557.USD","BK1147","01911","LU1969619763.USD","BK1583","BK1161"],"gpt_icon":0},{"id":"2609757865","title":"Innovent Biologics and Eli Lilly Announce Global Oncology and Immunology Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2609757865","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609757865?lang=en_us&edition=fundamental","pubTime":"2026-02-08 18:05","pubTimestamp":1770545116,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. has announced a strategic collaboration with Eli Lilly and Company to jointly develop novel medicines in the fields of oncology and immunology. This marks the seventh partnership between the two companies and aims to accelerate global development of Innovent's innovative pipeline. Under the agreement, Innovent will lead early-stage development through Phase 2 clinical trials in China, while Lilly will have exclusive rights to develop and commercialize these medicines outside Greater China. Innovent will receive a $350 million upfront payment and could earn up to $8.5 billion in milestone payments, as well as tiered royalties on sales outside Greater China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260208:nNDL59ms5S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828714.EUR","01911","LU2097828474.EUR","LU0455707207.USD","BK1147","LU2097828557.USD","LU2097828805.USD","LU2488822045.USD","BK1161","BK1589","LU0502904849.HKD","LU1969619763.USD","HK0000165453.HKD","BK1583","LU2328871848.SGD","01801","LU2242644610.SGD","LU2097828631.EUR"],"gpt_icon":0},{"id":"2608357471","title":"Innovent Biologics Reports 45% Year-Over-Year Growth in 2025 Product Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2608357471","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608357471?lang=en_us&edition=fundamental","pubTime":"2026-02-04 18:21","pubTimestamp":1770200503,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. announced that its total product revenue for the full year of 2025 reached approximately RMB11.9 billion, reflecting a year-over-year growth of around 45%. In the fourth quarter of 2025, the company reported product revenue of approximately RMB3.3 billion, marking a strong year-over-year increase. The company also noted that it recognized inventory price adjustments in the fourth quarter for products previously distributed at original prices. This adjustment was primarily attributed to the inclusion of six new drugs in the 2026 National Reimbursement Drug List . The financial information provided is based on internal management records and has not been audited or reviewed by external auditors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL45qrJZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","BK1583","01801","LU2488822045.USD","BK1147","LU2097828557.USD","LU2097828805.USD","LU0455707207.USD","LU2097828474.EUR","LU1969619763.USD","LU2097828631.EUR","BK1161","LU0502904849.HKD","LU2328871848.SGD","01911","HK0000165453.HKD","LU2097828714.EUR","LU2242644610.SGD"],"gpt_icon":0},{"id":"2606069222","title":"FDA Grants Fast Track Designation to Innovent's IBI3003 for Relapsed or Refractory Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2606069222","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606069222?lang=en_us&edition=fundamental","pubTime":"2026-01-27 08:00","pubTimestamp":1769472021,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc. announced that its anti-GPRC5D/BCMA/CD3 trispecific antibody, IBI3003, has received Fast Track Designation from the U.S. Food and Drug Administration  for the treatment of relapsed or refractory multiple myeloma in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. The designation is intended to facilitate the development and expedite the review of IBI3003, which is currently undergoing Phase 1/2 clinical trials in China and Australia, with plans to initiate similar trials in the United States.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nNDL5fvCDY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","BK1583","HK0000165453.HKD","LU0455707207.USD","BK1147","01911","LU2097828631.EUR","LU2328871848.SGD","BK1161","01801","LU2097828714.EUR","LU2097828474.EUR","LU2097828557.USD","LU2242644610.SGD","LU2488822045.USD","BK1589","LU2097828805.USD","LU0502904849.HKD"],"gpt_icon":0},{"id":"2602311894","title":"Innovent Biologics Reports Positive Phase 1b Results for IBI324 in Eye Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2602311894","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602311894?lang=en_us&edition=fundamental","pubTime":"2026-01-09 08:00","pubTimestamp":1767916821,"startTime":"0","endTime":"0","summary":"Innovent Biologics Inc., in collaboration with its partner Ollin Biosciences, has announced positive topline results from the randomized, head-to-head Phase 1b JADE clinical study. The study compared IBI324 , a next-generation VEGF/Ang2 bispecific antibody, to faricimab  in over 160 patients with diabetic macular edema  or wet age-related macular degeneration . According to the announcement, OLN324 demonstrated superior outcomes and is characterized by higher anti-Ang2 potency and a differentiated profile for first-line standard of care. Full results from the JADE study are scheduled to be presented at the Angiogenesis, Exudation, and Degeneration 2026 symposium on February 7, 2026. Innovent and Ollin plan to advance OLN324 into global Phase 3 studies for both DME and wAMD.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL1BjwzH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","LU2242644610.SGD","LU2097828805.USD","LU2097828557.USD","LU2097828631.EUR","BK1161","LU0502904849.HKD","HK0000165453.HKD","BK1583","LU2097828474.EUR","LU0455707207.USD","LU2097828714.EUR","01801","LU2488822045.USD","01911","BK1147","LU1969619763.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2601433466","title":"China Renaissance Holdings Insiders Made A Wise Decision By Selling CN¥7.5m Worth Of Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2601433466","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601433466?lang=en_us&edition=fundamental","pubTime":"2026-01-08 07:51","pubTimestamp":1767829875,"startTime":"0","endTime":"0","summary":"While China Renaissance Holdings Limited ( HKG:1911 ) shareholders have enjoyed a good week with stock up 14%, they...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/7132000-choice2-main-header/1585186691278","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/7132000-choice2-main-header/1585186691278"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/diversified-financials/hkg-1911/china-renaissance-holdings-shares/news/china-renaissance-holdings-insiders-made-a-wise-decision-by-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/diversified-financials/hkg-1911/china-renaissance-holdings-shares/news/china-renaissance-holdings-insiders-made-a-wise-decision-by-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01911","CN","BK1147"],"gpt_icon":0},{"id":"2595877264","title":"China Renaissance - Distressed Assets Portfolio I Are Non-Performing Personal Consumer Debts Owed to Fuzhou Qifu Financing Guarantee","url":"https://stock-news.laohu8.com/highlight/detail?id=2595877264","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595877264?lang=en_us&edition=fundamental","pubTime":"2025-12-31 22:01","pubTimestamp":1767189715,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nFWN3Y108S:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1147","01911"],"gpt_icon":0},{"id":"2595772574","title":"China Renaissance - Unit Buys Distressed Assets Portfolio I for RMB277.1 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2595772574","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595772574?lang=en_us&edition=fundamental","pubTime":"2025-12-31 22:01","pubTimestamp":1767189715,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nFWN3Y108S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1147","01911"],"gpt_icon":0},{"id":"2595772501","title":"China Renaissance Acquires Distressed Assets in Discloseable Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2595772501","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595772501?lang=en_us&edition=fundamental","pubTime":"2025-12-31 22:01","pubTimestamp":1767189683,"startTime":"0","endTime":"0","summary":"China Renaissance Holdings Ltd. announced that its wholly-owned subsidiary entered into agreements to acquire two portfolios of distressed assets. The acquisitions, valued at approximately RMB277.1 million and RMB31.2 million respectively, are considered discloseable transactions under Hong Kong Listing Rules, requiring an announcement but not shareholders' approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Renaissance Holdings Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 31, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL7QXJ4v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1147","01911"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chinarenaissance.com","stockEarnings":[{"period":"1week","weight":-0.0926},{"period":"1month","weight":-0.2576},{"period":"3month","weight":-0.2005},{"period":"6month","weight":-0.5107},{"period":"1year","weight":-0.0228},{"period":"ytd","weight":-0.1695}],"compareEarnings":[{"period":"1week","weight":-0.0265},{"period":"1month","weight":-0.0645},{"period":"3month","weight":-0.0187},{"period":"6month","weight":-0.0303},{"period":"1year","weight":0.0853},{"period":"ytd","weight":-0.0115}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"China Renaissance Holdings Ltd is a holding company that is primarily engaged in providing investment banking and investment management services. The Company operates in four segments. Investment Banking segment provides early to late stage financial advisory and mergers and acquisitions advisory services, equity underwriting, sales, trading, brokerage, research services and structured financial services. Investment Management segment provides fund and asset management and manages its own investments in funds. China Renaissance (CR) Securities segment provides investment banking and asset management business. Others segment mainly includes wealth management business and investment and management of own funds.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.099096},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.014364},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.049746},{"month":4,"riseRate":0.2,"avgChangeRate":-0.077146},{"month":5,"riseRate":0.2,"avgChangeRate":-0.049869},{"month":6,"riseRate":1,"avgChangeRate":0.143061},{"month":7,"riseRate":0.4,"avgChangeRate":0.051599},{"month":8,"riseRate":0.6,"avgChangeRate":0.100699},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.131486},{"month":10,"riseRate":0,"avgChangeRate":-0.130048},{"month":11,"riseRate":0.285714,"avgChangeRate":0.027229},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.035994}],"exchange":"SEHK","name":"CR HOLDINGS","nameEN":"CR HOLDINGS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CR HOLDINGS(01911),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CR HOLDINGS(01911) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CR HOLDINGS,01911,CR HOLDINGS股票,CR HOLDINGS股票老虎,CR HOLDINGS股票老虎国际,CR HOLDINGS行情,CR HOLDINGS股票行情,CR HOLDINGS股价,CR HOLDINGS股市,CR HOLDINGS股票价格,CR HOLDINGS股票交易,CR HOLDINGS股票购买,CR HOLDINGS股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CR HOLDINGS(01911),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CR HOLDINGS(01911) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}